MDXG MiMedx Group Inc.

MiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

MiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020.

A pre-recorded presentation will be available on the Events page of the Investors section of the Company’s website at beginning on November 25, 2020 at 5:00 PM Eastern Time and will be accessible for approximately 45 days.

About MiMedx

MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit .

Contact

Hilary Dixon

Investor Relations & Corporate Communications

770.651.9066



EN
24/11/2020

Underlying

MDXGMiMedx Group Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Launch of EPIXPRESS®

MIMEDX Announces Launch of EPIXPRESS® Next-Generation, Lyophilized Human Placental Allograft Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions. “I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRE...

20h / 52m 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) F...

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall To Present Six Posters Featuring the Company’s Latest Product Innovations MARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced ...

September 3, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 3, 2025Fireside Chat (1:35 PM ET): Lake Street BIG9 Best Ideas Growth Conference | New York, NYThursday, September 11, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their respective Cantor o...

August 27, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Re...

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today...

July 30, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

MIMEDX Announces Strategic Collaboration with Vaporox, Inc. Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights re...

July 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch